東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Enhancing rituximab therapy: Analyzi...

Kennedy, Adam David.

FindBook

Google Book

Amazon

博客來

Enhancing rituximab therapy: Analyzing the interaction between rituximab and the human complement pathway.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Enhancing rituximab therapy: Analyzing the interaction between rituximab and the human complement pathway./
作者:	Kennedy, Adam David.
面頁冊數:	216 p.
附註:	Adviser: Ronald P. Taylor.
Contained By:	Dissertation Abstracts International66-09B.
標題:	Health Sciences, Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3189294
ISBN:	9780542319419

Enhancing rituximab therapy: Analyzing the interaction between rituximab and the human complement pathway.
Kennedy, Adam David.

Enhancing rituximab therapy: Analyzing the interaction between rituximab and the human complement pathway. - 216 p.

Adviser: Ronald P. Taylor.

Thesis (Ph.D.)--University of Virginia, 2005.

Rituximab (RTX) is a chimeric monoclonal antibody (mAb) used for treatment of B cell lymphomas as well as for several autoimmune diseases. In vitro, RTX opsonization of CD20+ cells in the presence of serum promotes covalent deposition of large amounts of C3b(i) (C3 activation fragments) ultimately leading to cell lysis by the membrane attack complex. RTX-mediated C3b(i) deposition and cell killing are enhanced with the anti-C3b mAb 3E7; this enhancement does not occur with other anti-C3b(i) mAbs and killing is directed at B cells. Fluorescence microscopy experiments suggest that C3b(i) is co-localized with bound RTX on B cells. However, <12% of deposited C3b(i) co-precipitates with RTX, suggesting that most of the deposited C3b(i) is located in close proximity with RTX.

ISBN: 9780542319419Subjects--Topical Terms:

1017716
Health Sciences, Immunology.

Enhancing rituximab therapy: Analyzing the interaction between rituximab and the human complement pathway.
LDR:03199nam 2200313 a 45 001 970613
005 20110921
008 110921s2005 eng d
020 $a 9780542319419
035 $a (UMI)AAI3189294
035 $a AAI3189294
040 $a UMI $c UMI
100 1 $a Kennedy, Adam David. $3 1294652
245 1 0 $a Enhancing rituximab therapy: Analyzing the interaction between rituximab and the human complement pathway.
300 $a 216 p.
500 $a Adviser: Ronald P. Taylor.
500 $a Source: Dissertation Abstracts International, Volume: 66-09, Section: B, page: 4711.
502 $a Thesis (Ph.D.)--University of Virginia, 2005.
520 $a Rituximab (RTX) is a chimeric monoclonal antibody (mAb) used for treatment of B cell lymphomas as well as for several autoimmune diseases. In vitro, RTX opsonization of CD20+ cells in the presence of serum promotes covalent deposition of large amounts of C3b(i) (C3 activation fragments) ultimately leading to cell lysis by the membrane attack complex. RTX-mediated C3b(i) deposition and cell killing are enhanced with the anti-C3b mAb 3E7; this enhancement does not occur with other anti-C3b(i) mAbs and killing is directed at B cells. Fluorescence microscopy experiments suggest that C3b(i) is co-localized with bound RTX on B cells. However, <12% of deposited C3b(i) co-precipitates with RTX, suggesting that most of the deposited C3b(i) is located in close proximity with RTX.
520 $a Intravenous infusion of RTX, in non-human primates and CLL patients, leads to binding of RTX to B cells, rapid deposition of C3b(i), and clearance of CD20+ cells from the circulation. Infusion of RTX in patients with high circulating tumor burdens leads to depletion of serum complement activity, by consumption of component C2. RTX-mediated lysis of tumor cells requires all proteins of the classical complement pathway, and supplementing CLL patient sera (sera low in complement activity but containing RTX) with normal human serum or purified human C2 replenishes in vitro killing activity.
520 $a High dose RTX therapy in CLL patients is followed by recrudescence of malignant cells (CD45+CD19+) with an altered CD20 phenotype. After RTX infusion, CD20 is "shaved" from the B cell surface and CD20 is reduced (>90-95%) as ascertained by flow cytometry and Western blot analysis. The level of expression of several other protein markers remains approximately constant after RTX infusion. Thrice weekly low dose RTX therapy (20 mg/m2) leads to progressive decreases in malignant cells in the bloodstream and preserves the CD20 antigen for a longer period of time compared to standard RTX therapy (375 mg/m2). The "saving" mechanism proposed here utilizes the mononuclear phagocytic system; THP-1 cells remove CD20 from RTX-opsonized cells. The shaving mechanism as well as C3b(i) deposition on RTX-opsonized cells, are being studied in a SCID mouse model.
590 $a School code: 0246.
650 4 $a Health Sciences, Immunology. $3 1017716
650 4 $a Health Sciences, Oncology. $3 1018566
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0419
690 $a 0982
690 $a 0992
710 2 0 $a University of Virginia. $3 645578
773 0 $t Dissertation Abstracts International $g 66-09B.
790 $a 0246
790 1 0 $a Taylor, Ronald P., $e advisor
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3189294